SCHEMBL2851031

SCHEMBL2851031

CC(C)(C)OC(=O)N1CCN(c2cc(Br)cc3ccc(C=O)nc23)CC1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 5/20 0.46
KCNH2 Q12809 2/20 0.42
MAP4K4 O95819 1/20 0.41
SMARCA2 P51531 1/20 0.41
SMARCA4 P51532 1/20 0.41
PBRM1 Q86U86 1/20 0.41
CKS1B P61024 2/20 0.41
SKP1 P63208 2/20 0.41
SKP2 Q13309 2/20 0.41
LMNA P02545 2/20 0.40
ALDH1A1 P00352 1/20 0.40
MAPT P10636 1/20 0.40
POLB P06746 1/20 0.39
SMPD3 Q9NY59 1/20 0.38
ACHE P22303 1/20 0.38
SUV39H2 Q9H5I1 1/20 0.38
USP30 Q70CQ3 1/20 0.38
GPR119 Q8TDV5 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2850829 0.86 BACE1 (0.44) BACE1KCNH2MAP4K4SMARCA2SMARCA4
SCHEMBL2850831 0.86 BACE1 (0.44) BACE1KCNH2MAP4K4SMARCA2SMARCA4
SCHEMBL2848570 0.86 BACE1 (0.48) BACE1KCNH2MAP4K4SMARCA2SMARCA4
SCHEMBL14551197 0.84 CKS1B (0.45) BACE1MAP4K4SMARCA2SMARCA4PBRM1
SCHEMBL3710011 0.81 PDE4B (0.44) USP30GPR119
SCHEMBL25821197 0.80 CKS1B (0.45) BACE1MAP4K4SMARCA2SMARCA4PBRM1
SCHEMBL27202974 0.78 CKS1B (0.46) BACE1MAP4K4SMARCA2SMARCA4PBRM1
SCHEMBL2851071 0.78 BACE1 (0.44) BACE1KCNH2MAP4K4SMARCA2SMARCA4
SCHEMBL24187486 0.76 BACE1 (0.51) BACE1MAP4K4SMARCA2SMARCA4PBRM1
SCHEMBL30276655 0.76 BACE1 (0.51) BACE1MAP4K4SMARCA2SMARCA4PBRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2027108-B1 HISTAMINE RECEPTOR ANTAGONISTS COMPRISING AN AZEPIN CORE GLAXO GROUP LTD (GB) 2010-01-13 EP disclosed
US-20090181950-A1 Histamine Receptor Antagonists Comprising an Azepin Core GLAXO GROUP LIMITED (GB) 2009-07-16 US disclosed
EP-2027108-A1 HISTAMINE RECEPTOR ANTAGONISTS COMPRISING AN AZEPIN CORE Glaxo Group Limited (GB) 2009-02-25 EP disclosed
WO-2007135081-A1 HISTAMINE RECEPTOR ANTAGONISTS COMPRISING AN AZEPIN CORE GLAXO GROUP LIMITED (GB) 2007-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181950-A1 Histamine Receptor Antagonists Comprising an Azepin Core HRH2, HRH1, HRH4 BACE1 1697/4885KCNH2 808/4885MAP4K4 3395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.